Revision history of "AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes" (Q40336881)

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

13 May 2023

  • curprev 15:0715:07, 13 May 2023KrBot talk contribs 38,081 bytes −1 Set a claim value: title (P1476): AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes undo
  • curprev 15:0715:07, 13 May 2023KrBot talk contribs 38,082 bytes −1 Changed English label: AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes undo (restore)
  • curprev 15:0715:07, 13 May 2023KrBot talk contribs 38,083 bytes −1 Changed Asturian label: AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes undo (restore)

6 September 2021

30 August 2021

2 February 2019

21 December 2017

20 September 2017

19 September 2017